{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:28:26Z","timestamp":1785479306408,"version":"3.56.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1053\/j.seminhematol.2026.05.001","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T14:24:48Z","timestamp":1778423088000},"page":"51-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The paradox of HbSC disease\u2014Not so benign after all"],"prefix":"10.1053","volume":"63","author":[{"given":"Randolph B.","family":"Lyde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8285","authenticated-orcid":false,"given":"Enrico M.","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1053\/j.seminhematol.2026.05.001_bib0001","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"9757","key":"10.1053\/j.seminhematol.2026.05.001_bib0002","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.05.001_bib0003","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1182\/bloodadvances.2023009993","article-title":"It's high time to turn the spotlight on HbSC disease","volume":"7","author":"Oluwole","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease","volume":"325","author":"Platt","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.001_bib0006","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0007","article-title":"Mortality in the United States, 2022","author":"Kochanek","year":"2024"},{"issue":"4581","key":"10.1053\/j.seminhematol.2026.05.001_bib0008","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/180326a0","article-title":"Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin","volume":"180","author":"Ingram","year":"1957","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of Sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0010","series-title":"Sickle cell disease","first-page":"692","author":"Gladwin","year":"2021"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0011","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2015.12.016","article-title":"Crises in sickle cell disease","volume":"149","author":"Novelli","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.001_bib0012","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3324\/haematol.2014.120402","article-title":"The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease","volume":"100","author":"Rees","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0013","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.001_bib0014","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bjh.14693","article-title":"Association between oxidative stress and vascular reactivity in children with sickle cell anaemia and sickle haemoglobin C disease","volume":"178","author":"Mockesch","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcmd.2017.02.001","article-title":"Micro- and macrovascular function in children with sickle cell anaemia and sickle cell haemoglobin C disease","volume":"64","author":"Mockesch","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.001_bib0016","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3324\/haematol.2019.239350","article-title":"The molecular basis for the prothrombotic state in sickle cell disease","volume":"105","author":"Shet","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.103193","article-title":"Emerging pathways in thromboinflammation of sickle cell disease: novel findings in disease pathogenesis","volume":"9","author":"Ramadas","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0018","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ajh.20129","article-title":"Increased levels of soluble ICAM-1 in the plasma of sickle cell patients are reversed by hydroxyurea","volume":"76","author":"Conran","year":"2004","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0019","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3324\/haematol.2014.114587","article-title":"Elevated hypercoagulability markers in hemoglobin SC disease","volume":"100","author":"Colella","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0020","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/ejh.13607","article-title":"Oxidative stress, inflammation, blood rheology, and microcirculation in adults with sickle cell disease: effects of hydroxyurea treatment and impact of sickle cell syndrome","volume":"106","author":"Connes","year":"2021","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.001_bib0021","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood.V74.5.1823.1823","article-title":"Acceleration of hemoglobin C crystallization by hemoglobin S","volume":"74","author":"Lin","year":"1989","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0022","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/248527","article-title":"The properties of red blood cells from patients heterozygous for HbS and HbC (HbSC Genotype)","volume":"2011","author":"Hannemann","year":"2011","journal-title":"Anemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040811","article-title":"Effects of genotypes and treatment on oxygenscan parameters in sickle cell disease","volume":"10","author":"Boisson","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.001_bib0024","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/13860291251357796","article-title":"Differences in oxygen-gradient ektacytometry parameters and blood viscosity between patients with sickle cell anemia and patients with sickle cell-hemoglobin C disorder","volume":"90","author":"Connes","year":"2025","journal-title":"Clin Hemorheol Microcirc"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.001_bib0025","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3324\/haematol.2008.005371","article-title":"Red blood cell aggregation, aggregate strength and oxygen transport potential of blood are abnormal in both homozygous sickle cell anemia and sickle-hemoglobin C disease","volume":"94","author":"Tripette","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0026","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000519360","article-title":"Unusually high prevalence of stroke and cerebral vasculopathy in hemoglobin SC disease: a retrospective single institution study","volume":"145","author":"Sathi","year":"2022","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0027","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/CH-2012-1622","article-title":"Severe proliferative retinopathy is associated with blood hyperviscosity in sickle cell hemoglobin-C disease but not in sickle cell anemia","volume":"55","author":"Lemaire","year":"2013","journal-title":"Clin Hemorheol Microcirc"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.2024028136","article-title":"A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea","volume":"146","author":"Setayesh","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.001_bib0029","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2011.055202","article-title":"Hemoglobin sickle cell disease complications: a clinical study of 179 cases","volume":"97","author":"Lionnet","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.001_bib0030","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41433-018-0162-8","article-title":"The past, present and future management of sickle cell retinopathy within an African context","volume":"32","author":"Amissah-Arthur","year":"2018","journal-title":"Eye (Lond Engl)"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0031","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/jamaophthalmol.2020.5900","article-title":"Deep learning detection of sea fan neovascularization from ultra-widefield color fundus photographs of patients with sickle cell hemoglobinopathy","volume":"139","author":"Cai","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0032","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/JMDH.S90630","article-title":"Sickle cell retinopathy: improving care with a multidisciplinary approach","volume":"10","author":"Menaa","year":"2017","journal-title":"J Multidiscip Healthc"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0033","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.19523","article-title":"The clinical spectrum of HbSC sickle cell disease-not a benign condition","volume":"205","author":"Nelson","year":"2024","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.05.001_bib0034","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.nurpra.2022.06.006","article-title":"Sensorineural hearing loss in sickle cell disease: case reports","volume":"18","author":"Speller-Brown","year":"2022","journal-title":"J Nurse Pract"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0035","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/ajh.23717","article-title":"Association between relative systemic hypertension and otologic disorders in patients with sickle cell-hemoglobin C disorder","volume":"89","author":"Lemonne","year":"2014","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.001_bib0036","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.1910.00050330050003","article-title":"Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia","volume":"VI","author":"Herrick","year":"1910","journal-title":"Arch Intern Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.05.001_bib0037","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1073\/pnas.37.12.775","article-title":"A third abnormal hemoglobin associated with hereditary hemolytic anemia","volume":"37","author":"Itano","year":"1951","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2023.102776","article-title":"Mouse models of sickle cell disease: imperfect and yet very informative","volume":"104","author":"Kamimura","year":"2024","journal-title":"Blood Cells Mol Dis"},{"issue":"5339","key":"10.1053\/j.seminhematol.2026.05.001_bib0039","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.278.5339.873","article-title":"Knockout-transgenic mouse model of sickle cell disease","volume":"278","author":"Ryan","year":"1997","journal-title":"Sci (NY NY)"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0040","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2005-07-2839","article-title":"Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease","volume":"107","author":"Manci","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0041","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle cell disease\u2014Genetics, pathophysiology, clinical presentation and treatment","volume":"5","author":"Inusa","year":"2019","journal-title":"Int J Neonatal Screen"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.001_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076333","article-title":"Role of macrophages in sickle cell disease erythrophagocytosis and erythropoiesis","volume":"24","author":"Sesti-Costa","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.05.001_bib0043","doi-asserted-by":"crossref","first-page":"8622","DOI":"10.1182\/blood-2022-164738","article-title":"Sickle cell disease compromises the hematopoietic stem cells bone marrow niche with age","volume":"140","author":"Dabbah","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0044","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2215\/CJN.03940415","article-title":"Kidney disease among patients with Sickle cell disease, hemoglobin SS and SC","volume":"11","author":"Drawz","year":"2016","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V45.2.273.273","article-title":"Red cell life span in sickle cell-hemoglobin C disease with a note about sickle cell-hemoglobin O ARAB","volume":"45","author":"McCurdy","year":"1975","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0046","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0002-9343(78)90053-0","article-title":"Irreversibly sickled cells and red cell survival in sickle cell anemia: a study with both DF32P and 51CR","volume":"64","author":"McCurdy","year":"1978","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0047","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1365-2141.2002.03274.x","article-title":"Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease","volume":"116","author":"Gladwin","year":"2002","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.05.001_bib0048","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10096-010-1049-1","article-title":"Assessment of splenic function","volume":"29","author":"de Porto","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0049","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ajh.10001","article-title":"Hemoglobin S-C disease revisited: clinical study of 106 adults","volume":"68","author":"Koduri","year":"2001","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.05.001_bib0050","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1056\/NEJMoa035477","article-title":"Pulmonary hypertension as a risk factor for death in patients with sickle cell disease","volume":"350","author":"Gladwin","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0051","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1183\/09031936.00134410","article-title":"Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease","volume":"39","author":"Fonseca","year":"2012","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0052","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1005565","article-title":"A hemodynamic study of pulmonary hypertension in sickle cell disease","volume":"365","author":"Parent","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.001_bib0053","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/1117-1936.180339","article-title":"Avascular necrosis of the femoral head in sickle cell disease in Nigeria: a retrospective study","volume":"14","author":"Akinyoola","year":"2007","journal-title":"Niger Postgrad Med J"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.001_bib0054","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1053\/j.semperi.2013.04.006","article-title":"Sickle cell crisis and pregnancy","volume":"37","author":"Parrish","year":"2013","journal-title":"Semin Perinatol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0055","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/hematology.2023000497","article-title":"Managing pregnancy in patients with sickle cell disease from a transfusion perspective","volume":"2023","author":"Habibi","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0056","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-059491","article-title":"Prioritizing sickle cell disease","volume":"150","author":"Hsu","year":"2022","journal-title":"Pediatrics"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.05.001_bib0057","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2024-208784","article-title":"Maternal outcomes in pregnant women admitted with sickle cell disease: a retrospective study involving the National Inpatient sample (NIS 2016-2021) database","volume":"144","author":"Pokhriyal","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0058","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","article-title":"Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \u201cswitching\u201d agent. The multicenter study of hydroxyurea in sickle cell anemia","volume":"75","author":"Charache","year":"1996","journal-title":"Medicine"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.001_bib0059","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2141.2009.07602.x","article-title":"Pharmacotherapy in sickle cell disease \u2013 state of the art and future prospects","volume":"145","author":"Hankins","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.001_bib0060","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0197-2456(97)00014-7","article-title":"An extension of stochastic curtailment for incompletely reported and classified recurrent events: the Multicenter Study of hydroxyurea in Sickle cell anemia (MSH)","volume":"18","author":"McMahon","year":"1997","journal-title":"Control Clin Trials"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0061","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400402","article-title":"Hydroxyurea for children and adults with hemoglobin SC disease","volume":"4","author":"Dei-Adomakoh","year":"2025","journal-title":"NEJM Evid"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.05.001_bib0062","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2024-204408","article-title":"Double-blind, placebo-controlled randomized controlled trial of hydroxyurea for HbSC: results of the prospective identification of variables As outcomes for treatment (PIVOT) trial","volume":"144","author":"Dei-Adomakoh","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0063","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ajh.10328","article-title":"Role of phlebotomy in the management of hemoglobin SC disease: case report and review of the literature","volume":"73","author":"Markham","year":"2003","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.001_bib0064","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/1535370216639737","article-title":"Original research: use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease","volume":"241","author":"Summarell","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/13543780802708011","article-title":"Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia","volume":"18","author":"Ataga","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0066","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","volume":"153","author":"Ataga","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.001_bib0067","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.001_bib0068","first-page":"873","article-title":"Voxelotor: a hemoglobin S polymerization inhibitor for the treatment of sickle cell disease","volume":"11","author":"Yenamandra","year":"2020","journal-title":"J Adv Pract Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.001_bib0069","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2026.05.001_bib0070","unstructured":"Pfizer Inc. Pfizer voluntarily withdraws all lots of sickle cell disease treatment OXBRYTA\u00ae (voxelotor) from worldwide markets. Pfizer. 2024."},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.001_bib0071","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/cpt.70028","article-title":"Safety, pharmacokinetics, and pharmacodynamics of osivelotor for Sickle cell disease: first-in-human studies in healthy participants and patients","volume":"119","author":"Lisbon","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.001_bib0072","doi-asserted-by":"crossref","DOI":"10.1016\/j.brci.2025.100014","article-title":"Long-term mitapivat treatment is safe and efficacious in patients with sickle cell disease","volume":"1","author":"Conrey","year":"2025","journal-title":"Blood Red Cells Iron"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.05.001_bib0073","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for severe Sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.001_bib0074","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/s41591-025-03662-2","article-title":"Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1\/2 trial","volume":"31","author":"Grimley","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.001_bib0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T13:09:50Z","timestamp":1785330590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0037196326000399"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.05.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The paradox of HbSC disease\u2014Not so benign after all","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}